EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Serum GFAP levels correlate with astrocyte reactivity, post-mortem brain atrophy and neurofibrillary tangles

Pascual Sánchez-Juan iD, Elizabeth Valeriano-Lorenzo, Alicia Ruiz-González, Ana Belén Pastor, Hector Rodrigo Lara, Francisco López-González, María Ascensión Zea-Sevilla, Meritxell Valentí, Belen Frades, Paloma Ruiz, Laura Saiz, Iván Burgueño-García und 3 weitere

Brain · 03.05.2024 · 147 (5) · 1667-1679

DOI: 10.1093/brain/awae035 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Brain, online erschienen am 18.04.2024. Verfasst von Pascual Sánchez-Juan und 14 weiteren Autor:innen. Beteiligte Einrichtung: Alzheimer's Centre Reina Sofia-CIEN Foundation-ISCIII, Research Platforms, 28031 Madrid, Spain. Hauptthemen laut MEDLINE: Glial Fibrillary Acidic Protein, Astrocytes, Neurofibrillary Tangles, Atrophy. Die Arbeit wurde bisher 98-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Fundación Reina Sofia and Next Generation funding UE/Mecanismo de Recuperación y Resiliencia, ISCIII, Queen Sofia.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Glial fibrillary acidic protein (GFAP), a proxy of astrocyte reactivity, has been proposed as biomarker of Alzheimer’s disease. However, there is limited information about the correlation between blood biomarkers and post-mortem neuropathology. In a single-centre prospective clinicopathological cohort of 139 dementia patients, for which the time-frame between GFAP level determination and neuropathological assessment was exceptionally short (on average 139 days), we analysed this biomarker, measured at three time points, in relation to proxies of disease progression such as cognitive decline and brain weight. Most importantly, we investigated the use of blood GFAP to detect the neuropathological hallmarks of Alzheimer’s disease, while accounting for potential influences of the most frequent brain co-pathologies. The main findings demonstrated an association between serum GFAP level and post-mortem tau pathology (β = 12.85; P < 0.001) that was independent of amyloid deposits (β = 13.23; P = 0.02). A mediation analysis provided additional support for the role of astrocytic activation as a link between amyloid and tau pathology in Alzheimer’s disease. Furthermore, a negative correlation was observed between pre-mortem serum GFAP and brain weight at post-mortem (r = −0.35; P < 0.001). This finding, together with evidence of a negative correlation with cognitive assessments (r = −0.27; P = 0.005), supports the role of GFAP as a biomarker for disease monitoring, even in the late phases of Alzheimer’s disease. Moreover, the diagnostic performance of GFAP in advanced dementia patients was explored, and its discriminative power (area under the receiver operator characteristic curve at baseline = 0.91) in differentiating neuropathologically-confirmed Alzheimer’s disease dementias from non-Alzheimer’s disease dementias was determined, despite the challenging scenario of advanced age and frequent co-pathologies in these patients. Independently of Alzheimer’s disease, serum GFAP levels were shown to be associated with two other pathologies targeting the temporal lobes—hippocampal sclerosis (β = 3.64; P = 0.03) and argyrophilic grain disease (β = −6.11; P = 0.02). Finally, serum GFAP levels were revealed to be correlated with astrocyte reactivity, using the brain GFAP-immunostained area as a proxy (ρ = 0.21; P = 0.02). Our results contribute to increasing evidence suggesting a role for blood GFAP as an Alzheimer’s disease biomarker, and the findings offer mechanistic insights into the relationship between blood GFAP and Alzheimer’s disease neuropathology, highlighting its ties with tau burden. Moreover, the data highlighting an independent association between serum GFAP levels and other neuropathological lesions provide information for clinicians to consider when interpreting test results. The longitudinal design and correlation with post-mortem data reinforce the robustness of our findings. However, studies correlating blood biomarkers and neuropathological assessments are still scant, and further research is needed to replicate and validate these results in diverse populations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glial Fibrillary Acidic ProteinAstrocytesNeurofibrillary TanglesAtrophyAlzheimer DiseaseBrainBiomarkersHumansFemaleMaleAgedAged, 80 and overAutopsytau ProteinsProspective StudiesMiddle AgedDisease ProgressionDementia

Stichwörter der Autor:innen

Alzheimer’s diseaseastrocyteblood biomarkersneuropathologytau

Substanzen

Glial Fibrillary Acidic ProteinGFAP protein, humanBiomarkerstau Proteins

Autor:innen und Institutionen

  • Alzheimer's Centre Reina Sofia-CIEN Foundation-ISCIII, Research Platforms, 28031 Madrid, Spain.
  • CIBERNED, Network Center for Biomedical Research in Neurodegenerative Diseases, 28029 Madrid, Spain.
  • Banco de Cerebros de la Región de Murcia, Neuropathology Department, 30120 Murcia, Spain.
  • Chronic Disease Programme, Instituto de Salud Carlos III, Madrid, Spain.

ORCID-Profile: Pascual Sánchez-Juan, Alberto Rábano

Förderung

  • Fundación Reina Sofia and Next Generation funding UE/Mecanismo de Recuperación y Resiliencia
  • ISCIII
  • Queen Sofia

Zitieren

APA

Sánchez-Juan, P., Valeriano-Lorenzo, E., Ruiz-González, A., Pastor, A. B., Rodrigo Lara, H., López-González, F., Zea-Sevilla, M. A., Valentí, M., Frades, B., Ruiz, P., Saiz, L., Burgueño-García, I., Calero, M., Del Ser, T., & Rábano, A. (2024). Serum GFAP levels correlate with astrocyte reactivity, post-mortem brain atrophy and neurofibrillary tangles. Brain, 147(5), 1667-1679. https://doi.org/10.1093/brain/awae035

Vancouver

Sánchez-Juan P, Valeriano-Lorenzo E, Ruiz-González A, Pastor AB, Rodrigo Lara H, López-González F, et al. Serum GFAP levels correlate with astrocyte reactivity, post-mortem brain atrophy and neurofibrillary tangles. Brain. 2024;147(5):1667-1679. doi:10.1093/brain/awae035

BibTeX
@article{SnchezJuan2024,
  author = {Sánchez-Juan, Pascual and Valeriano-Lorenzo, Elizabeth and Ruiz-González, Alicia and Pastor, Ana Belén and Rodrigo Lara, Hector and López-González, Francisco and Zea-Sevilla, María Ascensión and Valentí, Meritxell and Frades, Belen and Ruiz, Paloma and Saiz, Laura and Burgueño-García, Iván and Calero, Miguel and Del Ser, Teodoro and Rábano, Alberto},
  title = {Serum GFAP levels correlate with astrocyte reactivity, post-mortem brain atrophy and neurofibrillary tangles},
  journal = {Brain},
  year = {2024},
  volume = {147},
  number = {5},
  pages = {1667--1679},
  doi = {10.1093/brain/awae035}
}
Kostenlos starten →